Literature DB >> 12063521

Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma.

Yukio Kawagishi1, Haruhisa Mita, Masami Taniguchi, Muneharu Maruyama, Rokuo Oosaki, Noritaka Higashi, Tatsuhiko Kashii, Masashi Kobayashi, Kazuo Akiyama.   

Abstract

BACKGROUND: The A to C transversion in the promoter region of the gene encoding leukotriene C4 synthase (LTC4S) is proposed to be associated with the development of aspirin-induced asthma (AIA).
OBJECTIVE: We investigated the frequency of the polymorphism in Japanese population and its association with clinical characteristics and cysteinyl leukotriene production.
METHODS: Genotyping of LTC4S gene promoter was performed on 60 patients with AIA, 100 patients with aspirin-tolerant asthma (ATA), and 110 control subjects. We assessed the basal levels of urinary LTE4, the increment of urinary LTE4 on venous aspirin challenge, and LTC4S activity in peripheral blood eosinophils.
RESULTS: The frequency of the variant C allele was significantly higher in patients with AIA (frequency of allele [q] = 0.192) than in patients with ATA (q = 0.110, P =.042). Variant C-allelic carriers experienced asthma at a significantly younger age (31.8 +/- 2.9 years [mean +/- SEM]) than wild-type A homozygotes (41.3 +/- 2.2 years, P =.007). Basal levels of LTE4 and the increment of urinary LTE4 on venous aspirin challenge did not show a difference between wild-type A homozygotes and variant C-allelic carriers. There was no relationship between the polymorphism and the LTC4S activity in eosinophils, although LTC4S activities were significantly higher in patients with AIA than in patients with ATA.
CONCLUSION: Our findings reveal the lack of functionality of the polymorphism in the LTC4S gene, whereas this polymorphism might have some effect on the development of AIA, probably in linkage disequilibrium with another causatively important mutation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12063521     DOI: 10.1067/mai.2002.124466

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  23 in total

1.  ADAM33 polymorphisms are associated with aspirin-intolerant asthma in the Japanese population.

Authors:  Takuro Sakagami; Nobuyoshi Jinnai; Toshiaki Nakajima; Takashi Sekigawa; Takashi Hasegawa; Eiichi Suzuki; Ituro Inoue; Fumitake Gejyo
Journal:  J Hum Genet       Date:  2006-10-24       Impact factor: 3.172

2.  Association of Leukotriene C4 Synthase A-444C Polymorphism with Asthma and Asthma Phenotypes in Romanian Population.

Authors:  Elene Camelia Berghea; Luis O Popa; Monica I Dutescu; Mihaela Meirosu; Ileana C Farcasanu; Florian Berghea; Constantin Bara; Olivia M Popa
Journal:  Maedica (Buchar)       Date:  2015-06

3.  Functional promoter polymorphism in the TBX21 gene associated with aspirin-induced asthma.

Authors:  Mitsuteru Akahoshi; Kazuhiko Obara; Tomomitsu Hirota; Akira Matsuda; Koichi Hasegawa; Naomi Takahashi; Makiko Shimizu; Kazuko Nakashima; Lei Cheng; Satoru Doi; Hiroshi Fujiwara; Akihiko Miyatake; Kimie Fujita; Noritaka Higashi; Masami Taniguchi; Tadao Enomoto; Xiao-Quan Mao; Hitoshi Nakashima; Chaker N Adra; Yusuke Nakamura; Mayumi Tamari; Taro Shirakawa
Journal:  Hum Genet       Date:  2005-04-02       Impact factor: 4.132

Review 4.  Leukotrienes and airway inflammation.

Authors:  Katsuhide Okunishi; Marc Peters-Golden
Journal:  Biochim Biophys Acta       Date:  2011-02-23

Review 5.  Genetics and pharmacogenetics of the leukotriene pathway.

Authors:  Kelan G Tantisira; Jeffrey M Drazen
Journal:  J Allergy Clin Immunol       Date:  2009-08-08       Impact factor: 10.793

Review 6.  Aspirin-induced asthma: clinical aspects, pathogenesis and management.

Authors:  Ahmed M Hamad; Amy M Sutcliffe; Alan J Knox
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 7.  Benefit-risk assessment of antileukotrienes in the management of asthma.

Authors:  Luis García-Marcos; Antje Schuster; Eduardo G Pérez-Yarza
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 8.  Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal.

Authors:  Chaouki K Khoury; James R Couch
Journal:  Drug Des Devel Ther       Date:  2010-02-18       Impact factor: 4.162

9.  Aspirin-exacerbated asthma.

Authors:  Mathew Varghese; Richard F Lockey
Journal:  Allergy Asthma Clin Immunol       Date:  2008-06-15       Impact factor: 3.406

10.  Genome-wide and follow-up studies identify CEP68 gene variants associated with risk of aspirin-intolerant asthma.

Authors:  Jeong-Hyun Kim; Byung-Lae Park; Hyun Sub Cheong; Joon Seol Bae; Jong Sook Park; An Soo Jang; Soo-Taek Uh; Jae-Sung Choi; Yong-Hoon Kim; Mi-Kyeong Kim; Inseon S Choi; Sang Heon Cho; Byoung Whui Choi; Choon-Sik Park; Hyoung Doo Shin
Journal:  PLoS One       Date:  2010-11-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.